Collegium Pharmaceutical, Inc. COLL Excise tax on share repurchases in accrued liabilities
Excise tax on share repurchases in accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept coll:ShareRepurchaseProgramExciseTaxIncludedInAccruedLiabilities.
The official record: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s excise tax on share repurchases in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s excise tax on share repurchases in accrued liabilities?
- Collegium Pharmaceutical, Inc. (COLL) reported excise tax on share repurchases in accrued liabilities of $0 in Q4 2025.
- How has Collegium Pharmaceutical, Inc.'s excise tax on share repurchases in accrued liabilities changed year-over-year?
- Collegium Pharmaceutical, Inc.'s excise tax on share repurchases in accrued liabilities decreased by 100.0% year-over-year, from $24.75K to $0.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s excise tax on share repurchases in accrued liabilities?
- Over 2 years (2023 to 2025), Collegium Pharmaceutical, Inc.'s excise tax on share repurchases in accrued liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $457K to $0.
- What does excise tax on share repurchases in accrued liabilities mean?
- This metric represents the liability accrued for the federal excise tax imposed on the net value of corporate stock repurchases. It reflects the company's obligation to pay taxes on buyback activity as mandated by current tax legislation. Monitoring this helps investors understand the total cash impact and regulatory costs associated with returning capital to shareholders.